GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Unipharma Co Ltd (ROCO:6621) » Definitions » EV-to-FCF

Unipharma Co (ROCO:6621) EV-to-FCF : -21.30 (As of Apr. 07, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Unipharma Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Unipharma Co's Enterprise Value is NT$365.39 Mil. Unipharma Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-17.16 Mil. Therefore, Unipharma Co's EV-to-FCF for today is -21.30.

The historical rank and industry rank for Unipharma Co's EV-to-FCF or its related term are showing as below:

ROCO:6621' s EV-to-FCF Range Over the Past 10 Years
Min: -120.69   Med: -14.32   Max: 105.13
Current: -25.33

During the past 12 years, the highest EV-to-FCF of Unipharma Co was 105.13. The lowest was -120.69. And the median was -14.32.

ROCO:6621's EV-to-FCF is ranked worse than
100% of 547 companies
in the Drug Manufacturers industry
Industry Median: 24.12 vs ROCO:6621: -25.33

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-07), Unipharma Co's stock price is NT$14.35. Unipharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-0.700. Therefore, Unipharma Co's PE Ratio (TTM) for today is At Loss.


Unipharma Co EV-to-FCF Historical Data

The historical data trend for Unipharma Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unipharma Co EV-to-FCF Chart

Unipharma Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.41 -14.75 -12.04 89.58 -20.23

Unipharma Co Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.04 - 89.58 - -20.23

Competitive Comparison of Unipharma Co's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Unipharma Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Unipharma Co's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Unipharma Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Unipharma Co's EV-to-FCF falls into.


;
;

Unipharma Co EV-to-FCF Calculation

Unipharma Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=365.394/-17.156
=-21.30

Unipharma Co's current Enterprise Value is NT$365.39 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Unipharma Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-17.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Unipharma Co  (ROCO:6621) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Unipharma Co's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=14.35/-0.700
=At Loss

Unipharma Co's share price for today is NT$14.35.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Unipharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-0.700.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Unipharma Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Unipharma Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Unipharma Co Business Description

Traded in Other Exchanges
N/A
Address
Jiu Zong Road, 3rd Floor, No. 17, Lane 171, Section 2, NeiHu District, Taipei, TWN, 11494
Unipharma Co Ltd is a medical diagnostic, pharmaceutical and medical device company. It is engaged in developing drug products and medical equipment. The company's products offerings include Baxter, Tambocor tablets, Bain Injection, Esmolol HCL Injection, Naloxone Injection, and SAM Pelvic Sling medical device. Its customers are major medical centers, regional hospitals, regional hospitals, and clinics.

Unipharma Co Headlines

No Headlines